Patents by Inventor Michael Riel-Mehan
Michael Riel-Mehan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220065872Abstract: The present application includes biomarkers, methods, devices, reagents, systems, and kits for the detection and diagnosis of non-small cell lung cancer and general cancer. In one aspect, the application provides biomarkers that can be used alone or in various combinations to diagnose non-small cell lung cancer or general cancer. In another aspect, methods are provided for diagnosing non-small cell lung cancer in an individual, where the methods include detecting, in a biological sample from an individual, at least one biomarker value corresponding to at least one biomarker selected from the group of biomarkers provided in Table 1, wherein the individual is classified as having lung cancer, or the likelihood of the individual having lung cancer is determined, based on the at least one biomarker value.Type: ApplicationFiled: September 21, 2021Publication date: March 3, 2022Applicant: SomaLogic, Inc.Inventors: Michael RIEL-MEHAN, Alex A. E. STEWART, Rachel M. OSTROFF, Stephen Alaric WILLIAMS, Edward N. Brody
-
Patent number: 11221340Abstract: The present application includes biomarkers, methods, devices, reagents, systems, and kits for the detection and diagnosis of lung cancer. In one aspect, the application provides biomarkers that can be used alone or in various combinations to diagnose lung cancer or permit the differential diagnosis of pulmonary nodules as benign or malignant. In another aspect, methods are provided for diagnosing lung cancer in an individual, where the methods include detecting, in a biological sample from an individual, at least one biomarker value corresponding to at least one biomarker selected from the group of biomarkers provided in Table 18, Table 20, or Table 21, wherein the individual is classified as having lung cancer, or the likelihood of the individual having lung cancer is determined, based on the at least one biomarker value.Type: GrantFiled: May 30, 2018Date of Patent: January 11, 2022Assignee: SomaLogic, Inc.Inventors: Sheri K. Wilcox, Deborah Ayers, Nebojsa Janjic, Larry Gold, Michael Riel-Mehan, Thale Jarvis
-
Patent number: 11041866Abstract: The present disclosure includes biomarkers, methods, devices, reagents, systems, and kits for the detection and diagnosis of cancer generally and pancreatic cancer specifically. In one aspect, the disclosure provides biomarkers that can be used alone or in various combinations to diagnose cancer generally or pancreatic cancer specifically. In another aspect, methods are provided for diagnosing pancreatic cancer in an individual, where the methods include detecting, in a biological sample from an individual, at least one biomarker value corresponding to at least one biomarker selected from the group of biomarkers provided in Table 1, wherein the individual is classified as having pancreatic cancer, or the likelihood of the individual having pancreatic cancer is determined, based on the at least one biomarker value.Type: GrantFiled: August 17, 2017Date of Patent: June 22, 2021Assignee: SomaLogic, Inc.Inventors: Stephen Alaric Williams, Michael Riel-Mehan, Rachel M. Ostroff
-
Publication number: 20180275143Abstract: The present application includes biomarkers, methods, devices, reagents, systems, and kits for the detection and diagnosis of lung cancer. In one aspect, the application provides biomarkers that can be used alone or in various combinations to diagnose lung cancer or permit the differential diagnosis of pulmonary nodules as benign or malignant. In another aspect, methods are provided for diagnosing lung cancer in an individual, where the methods include detecting, in a biological sample from an individual, at least one biomarker value corresponding to at least one biomarker selected from the group of biomarkers provided in Table 18, Table 20, or Table 21, wherein the individual is classified as having lung cancer, or the likelihood of the individual having lung cancer is determined, based on the at least one biomarker value.Type: ApplicationFiled: May 30, 2018Publication date: September 27, 2018Inventors: Sheri K. Wilcox, Deborah Ayers, Nebojsa Janjic, Larry Gold, Michael Riel-Mehan, Thale Jarvis
-
Publication number: 20180211722Abstract: An insulin activity map is a tool for assessing a patient's metabolic risk, designing a treatment plan, disseminating the information in a useful way to the patient, and encouraging the patient to remain on a treatment course. The insulin activity map combines a variety of inputs such as insulin sensitivity and insulin production to generate a patient-specific diagnosis and treatment assessment. The insulin activity map fills an important gap in prior art testing methods, providing diagnostic insights that improve clinician and patient understanding of the progression of diabetes, allows at-risk patients to more easily avoid developing diabetes, and helps diabetic and prediabetic patients manage and control the disease.Type: ApplicationFiled: January 23, 2018Publication date: July 26, 2018Inventors: Michael Dansinger, Michael Riel-Mehan, Julia Maddalena
-
Publication number: 20180045739Abstract: The present disclosure includes biomarkers, methods, devices, reagents, systems, and kits for the detection and diagnosis of cancer generally and pancreatic cancer specifically. In one aspect, the disclosure provides biomarkers that can be used alone or in various combinations to diagnose cancer generally or pancreatic cancer specifically. In another aspect, methods are provided for diagnosing pancreatic cancer in an individual, where the methods include detecting, in a biological sample from an individual, at least one biomarker value corresponding to at least one biomarker selected from the group of biomarkers provided in Table 1, wherein the individual is classified as having pancreatic cancer, or the likelihood of the individual having pancreatic cancer is determined, based on the at least one biomarker value.Type: ApplicationFiled: August 17, 2017Publication date: February 15, 2018Inventors: Stephen Alaric Williams, Michael Riel-Mehan, Rachel M. Ostroff
-
Publication number: 20160327579Abstract: A method is provided for transforming one or more biomarkers into a cholesterol efflux capacity (CEC) value. Methods relate to determining SR-BI-mediated and ABCA1-mediated CEC. CEC may be used for compound screening and to determine risk of cardiovascular disease and to recommend or administer treatment regimens.Type: ApplicationFiled: June 19, 2015Publication date: November 10, 2016Inventors: Bela F. Asztalos, Michael Riel-mehan, Ernst J. Schaefer
-
Publication number: 20160327578Abstract: A method is provided for transforming one or more biomarkers into a cholesterol efflux capacity (CEC) level. Methods relate to determining SR-BI-mediated and ABCA1-mediated CEC. CEC may be used for compound screening and to determine risk of cardiovascular disease and to recommend or administer treatment regimens.Type: ApplicationFiled: May 7, 2015Publication date: November 10, 2016Inventors: Bela F. Asztalos, Michael Riel-Mehan, Ernst J. Schaefer
-
Publication number: 20150160225Abstract: The subject disclosure concerns methods for evaluation of renal cell carcinoma (RCC). Such methods include a method of determining of a diagnosis of the individual as having or not having RCC; determination of a prognosis of a future course of RCC; determination of disease burden; or determination of recurrence of RCC in an individual who had been apparently cured of RCC. The methods each involve the detection of the value of at least one biomarker of Table 1. The biomarker value is used, in some of the methods, to determine whether the individual does or does not demonstrate evidence of disease, and in another method, to determine the degree or a score indicative of the individual's extent of disease.Type: ApplicationFiled: December 10, 2014Publication date: June 11, 2015Inventors: Rachel M. Ostroff, Stephen Alaric Williams, Michael Riel-Mehan, Edward N. Brody, Alex A.E. Stewart, Shintaro Kato
-
Publication number: 20140073521Abstract: The present disclosure includes biomarkers, methods, devices, reagents, systems, and kits for the detection and diagnosis of cancer. In one aspect, methods are provided for diagnosing mesothelioma where the methods include detecting, in a biological sample, at least one biomarker value corresponding to at least one biomarker selected from the biomarkers provided in Table 1, wherein an individual is classified as having mesothelioma, or the likelihood of an individual having mesothelioma is determined, based on the at least one biomarker value. In another aspect, methods are provided for diagnosing cancer generally where the methods include detecting, in a biological sample at least one biomarker value corresponding to at least one biomarker selected from the biomarkers provided in Table 17, wherein an individual is classified as having cancer generally, or the likelihood of an individual having cancer is determined, based on the at least one biomarker value.Type: ApplicationFiled: September 3, 2013Publication date: March 13, 2014Applicant: SomaLogic, Inc.Inventors: Rachel M. Ostroff, Alex A.E. Stewart, Stephen Alaric Williams, Edward N. Brody, Malti Nikrad, Michael Riel-Mehan
-
Publication number: 20140073522Abstract: The present disclosure includes biomarkers, methods, devices, reagents, systems, and kits for the detection and diagnosis of cancer generally and pancreatic cancer specifically. In one aspect, the disclosure provides biomarkers that can be used alone or in various combinations to diagnose cancer generally or pancreatic cancer specifically. In another aspect, methods are provided for diagnosing pancreatic cancer in an individual, where the methods include detecting, in a biological sample from an individual, at least one biomarker value corresponding to at least one biomarker selected from the group of biomarkers provided in Table 1, wherein the individual is classified as having pancreatic cancer, or the likelihood of the individual having pancreatic cancer is determined, based on the at least one biomarker value.Type: ApplicationFiled: September 6, 2013Publication date: March 13, 2014Applicant: SomaLogic, Inc.Inventors: Stephen Alaric Williams, Michael Riel-Mehan, Rachel M. Ostroff
-
Publication number: 20130116150Abstract: The present application includes biomarkers, methods, devices, reagents, systems, and kits for the detection and diagnosis of lung cancer. In one aspect, the application provides biomarkers that can be used alone or in various combinations to diagnose lung cancer or permit the differential diagnosis of pulmonary nodules as benign or malignant. In another aspect, methods are provided for diagnosing lung cancer in an individual, where the methods include detecting, in a biological sample from an individual, at least one biomarker value corresponding to at least one biomarker selected from the group of biomarkers provided in Table 18, Table 20, or Table 21, wherein the individual is classified as having lung cancer, or the likelihood of the individual having lung cancer is determined, based on the at least one biomarker value.Type: ApplicationFiled: July 11, 2011Publication date: May 9, 2013Applicant: SOMALOGIC, INC.Inventors: Sheri Wilcox, Deborah Ayers, Nebojsa Janjic, Larry Gold, Michael Riel-Mehan, Thale Jarvis
-
Publication number: 20130065782Abstract: The subject disclosure concerns methods for evaluation of renal cell carcinoma (RCC). Such methods include a method of determining of a diagnosis of the individual as having or not having RCC; determination of a prognosis of a future course of RCC; determination of disease burden; or determination of recurrence of RCC in an individual who had been apparently cured of RCC. The methods each involve the detection of the value of at least one biomarker of Table 1. The biomarker value is used, in some of the methods, to determine whether the individual does or does not demonstrate evidence of disease, and in another method, to determine the degree or a score indicative of the individual's extent of disease.Type: ApplicationFiled: August 22, 2012Publication date: March 14, 2013Applicant: SOMALOGIC, INC.Inventors: Rachel M. Ostroff, Stephen Alaric Williams, Michael Riel-Mehan, Edward N. Brody, Alex A.E. Stewart, Shintaro Kato
-
Publication number: 20120165217Abstract: The present disclosure includes biomarkers, methods, devices, reagents, systems, and kits for the detection and diagnosis of cancer. In one aspect, the disclosure provides biomarkers that can be used alone or in various combinations to diagnose cancer. In another aspect, methods are provided for diagnosing cancer in an individual, where the methods include detecting, in a biological sample from an individual, at least one biomarker value corresponding to at least one biomarker selected from the group of biomarkers provided in Table 24, wherein the individual is classified as having cancer, or the likelihood of the individual having cancer is determined, based on the at least one biomarker value.Type: ApplicationFiled: April 3, 2010Publication date: June 28, 2012Applicant: SOMALOGIC, INC.Inventors: Larry Gold, Edward N. Brody, Rachel M. Ostroff, Dominic Zichi, Alex A.E. Stewart, Michael Riel-Mehan, Mark Messenbaugh, Randee S. Schwartz, Jeffery Walker, Stephen Alaric Williams, Malti Nikrad
-
Publication number: 20120143805Abstract: The present disclosure includes biomarkers, methods, devices, reagents, systems, and kits for the detection and diagnosis of cancer. In one aspect, the disclosure provides biomarkers that can be used alone or in various combinations to diagnose cancer. In another aspect, methods are provided for diagnosing cancer in an individual, where the methods include detecting, in a biological sample from an individual, at least one biomarker value corresponding to at least one biomarker selected from the group of biomarkers provided in Table 47, wherein the individual is classified as having cancer, or the likelihood of the individual having cancer is determined, based on the at least one biomarker value.Type: ApplicationFiled: March 5, 2010Publication date: June 7, 2012Applicant: SOMALOGIC, INC.Inventors: Larry Gold, Edward N. Brody, Rachel M. Ostroff, Dominic Zichi, Alex A.E. Stewart, Michael Riel-Mehan, Mark Messenbaugh, Randee S. Schwartz, Jeffery Walker, Stephen Alaric Williams, Malti Nikrad
-
Publication number: 20120101002Abstract: The present disclosure includes biomarkers, methods, devices, reagents, systems, and kits for the detection and diagnosis of non-small cell lung cancer and general cancer. In one aspect, methods are provided for diagnosing non-small cell lung cancer, where the methods include detecting, in a sample, at least one biomarker value corresponding to at least one biomarker selected from the biomarkers provided in Table 1, wherein an individual is classified as having lung cancer, or the likelihood of having lung cancer is determined, based on the at least one biomarker value. In another aspect, methods are provided for diagnosing cancer, where the methods include detecting, in a sample, at least one biomarker value corresponding to at least one biomarker selected from the biomarkers provided in Table 19, wherein an individual is classified as having cancer, or the likelihood of having cancer is determined, based on the at least one biomarker value.Type: ApplicationFiled: October 24, 2011Publication date: April 26, 2012Applicant: SomaLogic, Inc.Inventors: Michael Riel-Mehan, Alex A.E. Stewart, Rachel M. Ostroff, Stephen Alaric Williams, Edward N. Brody
-
Publication number: 20120077695Abstract: The present disclosure includes biomarkers, methods, devices, reagents, systems, and kits for the detection and diagnosis of cancer. In one aspect, methods are provided for diagnosing mesothelioma where the methods include detecting, in a biological sample, at least one biomarker value corresponding to at least one biomarker selected from the biomarkers provided in Table 1, wherein an individual is classified as having mesothelioma, or the likelihood of an individual having mesothelioma is determined, based on the at least one biomarker value. In another aspect, methods are provided for diagnosing cancer generally where the methods include detecting, in a biological sample at least one biomarker value corresponding to at least one biomarker selected from the biomarkers provided in Table 17, wherein an individual is classified as having cancer generally, or the likelihood of an individual having cancer is determined, based on the at least one biomarker value.Type: ApplicationFiled: September 27, 2011Publication date: March 29, 2012Applicant: SOMALOGIC, INC.Inventors: Rachel M. Ostroff, Alex A.E. Stewart, Stephen Alaric Williams, Edward N. Brody, Malti Nikrad, Michael Riel-Mehan
-
Publication number: 20120040861Abstract: The present disclosure includes biomarkers, methods, devices, reagents, systems, and kits for the detection and diagnosis of cancer generally and pancreatic cancer specifically. In one aspect, the disclosure provides biomarkers that can be used alone or in various combinations to diagnose cancer generally or pancreatic cancer specifically. In another aspect, methods are provided for diagnosing pancreatic cancer in an individual, where the methods include detecting, in a biological sample from an individual, at least one biomarker value corresponding to at least one biomarker selected from the group of biomarkers provided in Table 1, wherein the individual is classified as having pancreatic cancer, or the likelihood of the individual having pancreatic cancer is determined, based on the at least one biomarker value.Type: ApplicationFiled: August 12, 2011Publication date: February 16, 2012Applicant: SOMALOGIC, INC.Inventors: Stephen Alaric Williams, Michael Riel-Mehan, Rachel M. Ostroff